ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNS

Core Viewpoint - A class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. for allegedly making materially false and misleading statements regarding the risks associated with their RAISE trial, which may have led to investor damages when the truth was revealed [1]. Group 1: Lawsuit Details - The lawsuit claims that defendants understated the risk of failing to meet early-stopping criteria in the RAISE trial [1]. - It is alleged that the defendants did not disclose that failing to meet these criteria could result in the cessation of the separate Phase 3 RAISE II trial [1]. - As a result, the statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading [1]. Group 2: Class Action Information - The Rosen Law Firm is reminding investors who purchased Marinus securities between March 17, 2021, and May 7, 2024, of the August 5, 2024, deadline to become a lead plaintiff in the class action [2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [4]. - To join the class action, investors can visit the provided link or contact the firm directly for more information [5][6].